A Pilot Study of the secondary prophylaxtic use of Hetrombopag in preventing Platinum-Based Chemotherapy inducedthrombocytopenia in Lung Cancer Patients

INTERVENTION: Prevention group 1 (Phase One):Standard chemotherapy: Hetrombopag 7.5mg once daily, starting on the day chemotherapy ends, taken continuously until completing 2 chemotherapy cycles (dose adjustable);Prevention group 2 (Phase One):Standard chemotherapy: Hetrombopag 7.5mg once daily, starting on the day each chemo cycle ends, for 14 days, until completing 2 chemo cycles (dose adjustable);Prevention group (Phase Two):Standard chemotherapy Hetrombopag;Control group (Phase Two):none; CONDITION: cancer therapy induced thrombocytopenia PRIMARY OUTCOME: Incidence of grade >=3 CTIT; SECONDARY OUTCOME: Incidence of chemotherapy dose reduction due to thrombocytopenia;Incidence of grade =2 CTIT;safety;Incidence of chemotherapy suspension or delay due to thrombocytopenia; INCLUSION CRITERIA: 1. Aged >=18 years old, male or female; 2. Patients with non‐small cell lung cancer (NSCLC) confirmed by histopathological or cytological examination; 3. Currently receiving carboplatin‐based antitumor therapy (AUC 5‐6, 21‐day chemotherapy cycle), including driver gene‐positive patients who are receiving carboplatin‐containing chemotherapy after prior TKI treatment; 4. Developed a platelet count <75×10^9/L due to the same anti‐tumor treatment regimen in the last cycle; 5. Platelet count between 80×10^9/L and <200×10^9/L within 3 days prior to enrollment; 6. An anticipated survival of at least 12 weeks at the time of screening, with the ability to tolerate a minimum of 2 cycles of the identical chemotherapy regimen; 7. Eastern Cooperative Oncology Group (ECOG) Performance Status score: 0‐2; 8. Laboratory examinations meeting the following requirements: (1) Renal function: Serum creatinine (Cr) <=1.5×upper limit of normal (ULN), creatinine clearan